Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Primary Myelofibrosis 39Myeloproliferative Disorders 30Leukemia, Myeloid, Acute 23Polycythemia Vera 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 17Myelodysplastic Syndromes 15Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 9Multiple Myeloma 9Graft vs Host Disease 9Breast Neoplasms 9Pancreatic Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hematologic Neoplasms 6Prostatic Neoplasms 5Lymphoma, T-Cell 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Hodgkin Disease 5Hematologic Diseases 5Colorectal Neoplasms 5Thrombocytosis 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Carcinoma, Non-Small-Cell Lung 4

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × ruxolitinib × Clear all
NCT06397313 2025-09-23

POTAMI-61

Ryvu Therapeutics SA

Phase 2 Recruiting
230 enrolled
Myeloid

Neoplasm Metastasis, Primary Myelofibrosis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡